Navigation Links
Genta Announces Senior Management Changes
Date:2/22/2008

BERKELEY HEIGHTS, N.J., Feb. 22 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) today announced that Richard J. Moran, Senior Vice-President and Chief Financial Officer, has indicated his intention to retire from the Company effective February 29, 2008. Upon Mr. Moran's retirement, Gary Siegel, currently Vice President of Finance, will assume the roles of Principal Accounting Officer and Principal Financial Officer. Mr. Siegel has served the Company for the past 5 years in financial roles of increasing responsibility. An executive recruitment firm, Spencer Stuart, has been engaged by Genta to assist in the search for Mr. Moran's successor. Mr. Moran has agreed to serve as a consultant to the Company to ensure a smooth transition during this period.

Genta also announced the appointment of Michael M. Yoshitsu, PhD, an experienced pharmaceutical executive, as Vice President, Global Business Development. In this capacity, Dr. Yoshitsu will lead activities related to in-licensing of new products, as well as partnering negotiations for the Company's existing products, including Genasense(R) (oblimersen sodium) Injection, Ganite(R) (gallium nitrate injection), and G4544, a new oral drug for accelerated bone loss. Mr. Yoshitsu's background appears below.

"On behalf of the Board, I want to thank Dick Moran for his years of outstanding service and contributions during his tenure at Genta," said Dr. Raymond P. Warrell, Jr., Chairman and Chief Executive Officer. "We are also pleased that Dr. Yoshitsu has agreed to join us in leading our key business development activities that are currently active on a number of fronts."

Biographical Sketch of Michael M. Yoshitsu, PhD

Dr. Yoshitsu has more than 20 years of expe
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Syngenta Licenses Chromatin Gene Stacking Technology
3. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
4. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
5. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
6. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
7. Genta Receives NASDAQ Non-Compliance Notice
8. Genta Receives Notice of Non-Compliance With NASDAQ Rule
9. Genta Incorporated to Present at the BIO CEO & Investor Conference
10. Genta Announces Common Stock Offering of Approximately $3.1 Million
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... transplant rejection occurs when the transplant recipient,s immune system ... it. It was previously thought that T cells, the ... by molecules known as chemokines in order to migrate ... Journal of Clinical Investigation , Fadi Lakkis and ... demonstrate that chemokine stimulation of T cells is not ...
(Date:5/17/2013)... provider of scientific, technical and medical information products and ... in Reproductive BioMedicine Online on ... abnormal chromosomal composition can be identified by the rate ... the risk of genetic abnormality without a biopsy. In ... retrospective study, using their predictive model to assess the ...
(Date:5/17/2013)... 2013 •    First of its kind research ... ,     New facility will help solve crop stresses ... Syngenta unveiled its new crop research facility during ... Innovation Center. The first of its kind, $72 million ... agricultural climate and precisely measure plant inputs – the ...
(Date:5/17/2013)... ALTO, Calif. , May 17, 2013 /PRNewswire/ ... it has achieved 50% enrollment of the total ... to evaluate the safety and preliminary efficacy of ... Cells) therapy for Knee Osteoarthritis (KOA). To date ... (SAE) reported. The Phase I open ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2
... Calif., March 10 MannKind,Corporation (Nasdaq: MNKD ... recent market events:, MannKind is absolutely committed ... Technosphere(R) Insulin. We use our small,patient-friendly Medtone(R) inhaler ... a way that much more closely matches the ...
... Judith K. Gwathmey VMD, Ph.D., FACC,FAHA has served ... Inc. for twelve years. Gwathmey, Inc. is an ... evaluation,of lead compounds prior to their conversion into ... a campaign with other members of the,quiet rural ...
... Anavex Life,Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today announced ... delay the growth of cancerous,tumors in patient-derived xenografts ... developed in ANAVEX labs using a sample,taken from ... cell sarcoma,is a rare type of melanoma (skin ...
Cached Biology Technology:MannKind Corporation Response to Recent Market Events 2MannKind Corporation Response to Recent Market Events 3MannKind Corporation Response to Recent Market Events 4MannKind Corporation Response to Recent Market Events 5MannKind Corporation Response to Recent Market Events 6Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 2Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 3Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 4Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 5Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 6
(Date:5/16/2013)... Fish fossils that are about 23 million years ... of the gobioid order, one of the most ... Researchers led by paleontologist Professor Bettina Reichenbacher from ... Department of Earth and Environmental Sciences at Ludwig-Maximilians-Universitaet ... comprehensive analysis of fish fossils which they assign ...
(Date:5/16/2013)... in Cameroon and the manager of San Diego Zoo ... prestigious Whitley award. The Whitley award is an ... because it celebrates the extraordinary achievements of some of ... Abwe was selected for the award due to his ... and its wildlife inhabitants., HRH The Princess Royal, the ...
(Date:5/15/2013)... moderating gout risk, new research reveals that vitamin C, ... (urate) levels to a clinically significant degree in patients ... combination with allopurinol, appears to have a weak effect ... to the results published in the American College of ... , Gout is an inflammatory arthritis that causes excruciating ...
Breaking Biology News(10 mins):Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3Vitamin C does not lower uric acid levels in gout patients 2
... Richard C. Willson has been named a 2010 Fellow ... (AAAS), which is the world,s largest general scientific society ... Willson is a professor of chemical and biomolecular engineering ... the AAAS for his "distinguished contributions to biomolecular recognition ...
... Conservation paleobiologists--scientists who use the fossil record to ... species to changes in their environment--are putting the ... the research in this emerging field provides examples ... environmental impacts, predict which species will be most ...
... Institute who have been studying prostate cancer cells for decades ... cancer progression. "This is the first demonstration of a ... a tumor to produce," said senior author Sal Pizzo, M.D., ... willing to bet there is also a connection in cancerous ...
Cached Biology News:University of Houston professor named 2010 AAAS Fellow 2Putting the dead to work 2Putting the dead to work 3Researchers learn why PSA levels reflect prostate cancer progression 2Researchers learn why PSA levels reflect prostate cancer progression 3
Rabbit Anti-conjugated Agmatine Polyclonal Antibody...
ABCA1 Immunogen: Mouse ABCA1-expressing HeLa stable transfectants. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Rabbit polyclonal to ADAMTS16 ( ... Antigen: Synthetic ... of human ADAMTS-16. Note: the amino ... Entrez GeneID: 170690 ...
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
Biology Products: